Gilead Sciences (GILD)
$77.83
2.51 (3.33%)
GILD Stock Quote Delayed 30 Minutes
Previous Close
$77.83
Market Cap
101.20B
PE Ratio
29.59
EPS
2.63
Volume (Avg. Vol.)
24.38M
Day's Range
74.61 - 78.12
52-Week Range
60.89 - 85.97
Dividend & Yield
2.23 (2.87%)
GILD Stock Predictions, Articles, and Gilead Sciences News
Remdesivir Can’t Cure Covid, But Good Luck Telling Gilead Stock
Gilead is moving into commercial production of Remdesivir, a COVID-19 treatment with an aggressive pricing model, but other biotech solutions could come out ahead; it's early days still.
Gilead Stock Is Worth Owning With or Without a Coronavirus Cure
GILD stock has been rallying, but it has been running out of momentum lately. Just don't lose focus on the positives for Gilead.
Stock Market Today: Coronavirus Treatments Make Progress; Nvidia to $425?
Nvidia caught a huge price target increase, while Apple looks to reopen its stores. Here's what happened in the stock market today.
Buy Good News Gilead Stock Before Other Investors Catch On
Positive signs continue to mount for remdesivir, yet the market continues to have mixed feelings about GILD stock.
Gilead Stock Still Looks Poised to Prove the Bears Wrong
With remdesivir poised to become a blockbuster drug for Gilead, GILD stock still looks poised to prove the bears wrong
9 Enduring Stocks That You Shouldn’t Sell in May
Under any other circumstance, sell in May and go away may be considered a sound strategy. In this crisis, though, you may want to keep these stocks to buy for the long haul.
Stock Market Today: Carnival Bookings Surge; Chesapeake on the Brink
Could the S&P 500 be heading for 3,000? Plus, Chesapeake Energy is on the brink. Here's what else happened in the stock market today.
Gilead Sciences Is a Strong Buy Despite What Its Detractors Might Say
Gilead Sciences is donating 1.5 million doses of remdesivir, which has many analysts bullish on GILD stock now.
Despite Gains, Threat, Gilead Is Still Attractive
GILD stock gets a boost from remdesivir, which has been approved as an emergency treatment for the coronavirus, Gilead still faces a threat.
Sell a Put on Capital One for Incredible Income
With some countries and states moving to reopen businesses, Capital One Financial Corporation (NYSE:COF) is an excellent target for a bullish put write.
3 Big Stock Charts for Thursday: Gilead Sciences, Boeing, and Nio
Thursday's big stock charts feature names that moved sharply on red-hot news stories
Dow Jones Today: Vaccine Hopes Overcame Contracting GDP
The remdesivir news took precedent over headlines about first-quarter GDP, which contracted 4.8%, or the worst shrinkage experienced by the world's largest economy since the dark days of the global financial crisis.
Stock Market Today: Small-Cap Stocks Are Back; Alphabet Rocks
Google's earnings boosted the Nasdaq, while small-cap stocks continue to roar to life. Here's what happened in the stock market today.
Buy Gilead Stock Because Remdesivir Is a Covid-19 Game-Changer
Gilead released more positive data on its Covid-19 treatment, remdesivir, laying the groundwork for bigger gains ahead for GILD stock.
The Cure for Profitably in Buying Gilead Sciences
GILD stock gets a lot of attention for its coronavirus therapy efforts, but the smart purchase of Gilead rests entirely on price action.
Stock Market Today: Small-Cap Stocks Roar to Life; GM Cuts Dividend
GM is cutting its dividend and Apple is delaying iPhone production. Here's what happened in the stock market today.
Don’t Let Negative Data Dissuade You from Gilead Sciences
Late last week, a Financial Times report suggested that Gilead’s coronavirus candidate drug remdesivir was not effective. However, the narrative for GILD stock requires a much broader context.
7 Beautiful Biotech Stocks to Buy Here
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
